search
Back to results

Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis

Primary Purpose

End Stage Renal Disease

Status
Completed
Phase
Phase 3
Locations
Mexico
Study Type
Interventional
Intervention
spironolactone
Placebo
Sponsored by
Instituto Nacional de Cardiologia Ignacio Chavez
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for End Stage Renal Disease focused on measuring spironolactone, peritoneal fibrosis, peritoneal dialysis

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age > 18
  • Hospitalized for peritoneal catheter placement for peritoneal dialysis

Exclusion Criteria:

  • Pregnancy
  • Hiperkalemia (K> 5.5meq/l)
  • Intolerance to spironolactone

Sites / Locations

  • Instituto Nacional de Cardiologia Ignacio Chavez

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

1

2

Arm Description

Peritoneal Dialysis patients on aldactone for 6 months

Peritoneal dialysis Patients on the placebo arm for 6 months

Outcomes

Primary Outcome Measures

Peritoneal fibrosis

Secondary Outcome Measures

Full Information

First Posted
March 17, 2009
Last Updated
October 23, 2012
Sponsor
Instituto Nacional de Cardiologia Ignacio Chavez
search

1. Study Identification

Unique Protocol Identification Number
NCT00865449
Brief Title
Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis
Official Title
Role of Renin Angiotensin Blockade in Peritoneal Fibrosis in Peritoneal Dialysis Patients
Study Type
Interventional

2. Study Status

Record Verification Date
March 2009
Overall Recruitment Status
Completed
Study Start Date
July 2008 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
March 2012 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Instituto Nacional de Cardiologia Ignacio Chavez

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This is a double blind randomized controlled study to evaluate the effect of aldactone on peritoneal fibrosis on incident peritoneal dialysis patients. The study would include a total of 40 incident peritoneal dialysis patients. Peritoneal biopsy would be made at randomization and 6 months after the intervention to evaluate the effect of renin angiotensin blockade on peritoneal fibrosis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease
Keywords
spironolactone, peritoneal fibrosis, peritoneal dialysis

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
20 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Description
Peritoneal Dialysis patients on aldactone for 6 months
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
Peritoneal dialysis Patients on the placebo arm for 6 months
Intervention Type
Drug
Intervention Name(s)
spironolactone
Intervention Description
25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Placebo, given daily for 6 months to Peritoneal Dialysis Patients
Primary Outcome Measure Information:
Title
Peritoneal fibrosis
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age > 18 Hospitalized for peritoneal catheter placement for peritoneal dialysis Exclusion Criteria: Pregnancy Hiperkalemia (K> 5.5meq/l) Intolerance to spironolactone
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Magdalena Madero, M.D
Organizational Affiliation
Instituto Nacional de Cardiologia Ignacio Chavez
Official's Role
Principal Investigator
Facility Information:
Facility Name
Instituto Nacional de Cardiologia Ignacio Chavez
City
Mexico
State/Province
DF
ZIP/Postal Code
14080
Country
Mexico

12. IPD Sharing Statement

Citations:
PubMed Identifier
33586138
Citation
Hasegawa T, Nishiwaki H, Ota E, Levack WM, Noma H. Aldosterone antagonists for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2021 Feb 15;2(2):CD013109. doi: 10.1002/14651858.CD013109.pub2.
Results Reference
derived

Learn more about this trial

Spironolactone and Prevention of Peritoneal Fibrosis in Peritoneal Dialysis

We'll reach out to this number within 24 hrs